Vanguard Global Advisers
PYXS icon

Vanguard Global Advisers’s Pyxis Oncology PYXS Stock Holding History

Vanguard Global Advisers’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.9K Hold
21,242
– – ﹤0.01% 2978
2026
Q1 		$31K Buy
+21,242
New +$32K ﹤0.01% 3185

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Global Advisers's PYXS Position: Q2 2026 in Review

Vanguard Global Advisers held its Pyxis Oncology (PYXS) position steady in Q2 2026 at 21,242 shares worth $63.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2978.

Vanguard Global Advisers first reported a position in PYXS in Q1 2026 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Vanguard Global Advisers held 21,242 shares of Pyxis Oncology worth $63.9K as of Q2 2026.
  • Vanguard Global Advisers left its Pyxis Oncology share count unchanged in Q2 2026.
  • Pyxis Oncology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2978 holding.
  • Vanguard Global Advisers first reported a position in Pyxis Oncology in Q1 2026 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.